Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 3,910 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostatic Cancer Clear all
Completed Not applicable Interventional

Internet-based System for Cancer Patients to Self-report Toxicity

NCT00578006
View directory record Official record
Conditions
Cervical Cancer, Lung Cancer, Prostate Cancer, Vaginal Cancer, Ovarian Cancer, Breast Cancer, Bladder Cancer
Interventions
Questioners, STAR website
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 24, 2026, 1:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449
View directory record Official record
Conditions
Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions
PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide, Giredestrant, Tamoxifen
Drug · Combination Product · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
14
States / cities
Los Angeles, California • New Haven, Connecticut • Trumbull, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 24, 2026, 1:27 AM EDT
Recruiting No phase listed Observational

Characterizing the Genomic Landscape of Cancer in Native American Populations (NAT-Geno)

NCT06960798
View directory record Official record
Conditions
Prostate Cancer, Renal Cell Carcinoma (RCC)
Interventions
Bio-specimen Collection, Blood Draw
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 1:27 AM EDT
Completed Not applicable Interventional Results available

Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)

NCT01215721
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Vesicare
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Oct 24, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer

NCT01341652
View directory record Official record
Conditions
Prostate Cancer
Interventions
pTVG-HP, rhGM-CSF
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 24, 2026, 1:27 AM EDT
Recruiting Not applicable Interventional

Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial

NCT07276438
View directory record Official record
Conditions
Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, CT-guided Stereotactic Body Radiation Therapy, Inter-fraction Adaptation of Treatment Plan, Magnetic Resonance Imaging, MRI-guided Stereotactic Body Radiation Therapy, Survey Administration
Procedure · Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 24, 2026, 1:27 AM EDT
Completed Phase 2 Interventional

An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy

NCT00686088
View directory record Official record
Conditions
Locally Recurrent Prostate Cancer
Interventions
PRX302
Drug
Lead sponsor
Sophiris Bio Corp
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
San Antonio, Texas • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2009 · Synced Oct 24, 2026, 1:27 AM EDT
Completed Not applicable Interventional

Optical Tomography in Prostate Cancer

NCT03215992
View directory record Official record
Conditions
Prostate Cancer
Interventions
Diffuse Optical Tomography (DOT) System
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 24, 2026, 1:27 AM EDT
Recruiting Phase 1 Interventional

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT07545811
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
Interventions
JANX014
Biological
Lead sponsor
Janux Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
La Jolla, California • St Louis, Missouri • Charleston, South Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 1:27 AM EDT
Completed Early Phase 1 Interventional

Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

NCT04266392
View directory record Official record
Conditions
Prostate Cancer
Interventions
[18F]-DCFPyl Ligand
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 24, 2026, 1:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Hemorrhagic Radiation Proctitis Using the Halo System

NCT01103492
View directory record Official record
Conditions
Pelvic Neoplasms
Interventions
HALO90 Ablation catheter
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 24, 2026, 1:27 AM EDT
Active, not recruiting Phase 2 Interventional

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

NCT03344211
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
Interventions
Enzalutamide, Laboratory Biomarker Analysis, Radium Ra 223 Dichloride
Drug · Other · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 24, 2026, 1:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Methylselenocysteine Effects on Circadian Rhythm

NCT01611038
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
Methylselenocysteine, Placebo
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 24, 2026, 1:27 AM EDT
Terminated Phase 1 Interventional

Study of ORIC-101 in Combination With Enzalutamide

NCT04033328
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
ORIC-101, enzalutamide 40 MG oral capsule [Xtandi]
Drug
Lead sponsor
ORIC Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
New York, New York • Myrtle Beach, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 24, 2026, 1:27 AM EDT
Recruiting Early Phase 1 Interventional

An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial

NCT06813898
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium, Positron Emission Tomography
Procedure · Other · Drug
Lead sponsor
Northwestern University
Other
Eligibility
Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 24, 2026, 1:27 AM EDT
Approved For Marketing No phase listed Expanded access

18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer

NCT04809584
View directory record Official record
Conditions
Prostate Cancer
Interventions
F18-DCFPyL, Gadolinium, Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 24, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

131-I-TM-601 Study in Adults With Solid Tumors

NCT00379132
View directory record Official record
Conditions
Breast Cancer, Non-Small Cell Lung Cancer, Melanoma, Colorectal Cancer, Pancreatic Cancer, Prostate Adenocarcinoma, Glioma, Primary Solid Tumors
Interventions
131-I-TM-601 (chlorotoxin)
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2009 · Synced Oct 24, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy

NCT00887458
View directory record Official record
Conditions
Prostate Cancer
Interventions
Itraconazole 200 mg, Itraconazole 300mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 24, 2026, 1:27 AM EDT
Suspended Phase 2 Interventional

Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

NCT05361915
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Metastatic
Interventions
Abivertinib, Abiraterone
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
La Jolla, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 24, 2026, 1:27 AM EDT
Terminated Phase 1 Interventional

Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer

NCT04887935
View directory record Official record
Conditions
Prostate Cancer, Cancer of Prostate
Interventions
Dapagliflozin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 24, 2026, 1:27 AM EDT
Terminated Not applicable Interventional Results available

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

NCT00147238
View directory record Official record
Conditions
Bladder Cancer, Genitourinary Cancer, Prostate Cancer
Interventions
Ferumoxtran-10 (USPIO), MR lymphangiography
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 24, 2026, 1:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

NCT04969315
View directory record Official record
Conditions
Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
Interventions
TT-10, TT-4
Drug
Lead sponsor
Portage Biotech
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 1:27 AM EDT
Recruiting Not applicable Interventional

Exploring the Potential of Robotic Telesurgery in Remote Settings

NCT07130708
View directory record Official record
Conditions
Prostate Carcinoma, Prostate Disease
Interventions
Telesurgery utilizing Microport Medbot Robotic Platform
Device
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 24, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

NCT01234025
View directory record Official record
Conditions
Castrate-Resistant Prostate Cancer
Interventions
ISIS EIF4E Rx, Prednisone, Docetaxel
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Fayetteville, Arkansas • San Bernardino, California • Fort Collins, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 24, 2026, 1:27 AM EDT